VTAK News & Events

Catheter Precision announced it has entered into a definitive agreement to divest its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer. Following a comprehensive portfolio review, the Company determined that monetizing these non-core assets enhances capital efficiency and sharpens focus on its high-growth electrophysiology platform. Transaction Highlights: Upfront cash payment following closing of $15,000; A 5% equity stake in the acquiring company with anti-dilution protection up to $5 million of additional equity capital being invested in the acquiring company; Ten-year royalty payments agreement on net sales: 1.5% baseline and Increases to 3% on quarterly net sales above $5 million.

Catheter Precision announced a strategic minority investment in Fly Flyte, an FAA-certified regional aviation operator utilizing AI-enabled operations and a growing fleet of Cirrus Vision Jets. Flyte conducts its flight operations through its wholly owned subsidiary, Ponderosa Air, operating under FAA 14 CFR Part 135, deploying Vision Jets across high-frequency short-haul regional routes where commercial airline capacity remains constrained. The company is generating revenue today with its fleet of Vision Jets, equipped with a proprietary whole-aircraft parachute system and Safe Return autonomous landing technology - advanced safety features that position the aircraft among the safest in the world. The transaction provides VTAK immediate exposure to an operating aviation business supported by tangible assets, scalable fleet expansion capability and technology-driven operating optimization. Transaction Overview: VTAK acquires 19.98% equity ownership in Flyte, aligning long-term strategic upside; Immediate exposure to one of the fastest-growing segments of private aviation; Asset-backed, scalable fleet expansion model; Preserves Flyte's operating continuity and strategic control; Creates optionality for increased ownership or future monetization.

Catheter Precision has agreed to the termination of its at-the-market equity offering program and has completed a strategic financing transaction with institutional investors for up to $36.5M to support accelerated growth. Key Highlights: ATM equity program to be terminated. No future equity lines of credit or forward-priced agreements are anticipated. Strategic institutional capital secured to fund expansion. Balance sheet and liquidity significantly strengthened. The company's short-term notes have been converted to long term by extending maturities out to two and three years. Additional short and long-term liabilities of approximately $9M on the 9/30/25 balance sheet are being converted into equity.